The activities are only open to registered delegates of CIC 2016

Tuesday, December 6 — 12:45-14:15


Pneumococcal disease causes severe infections such as meningitis, bacteraemia and pneumonia, with children and the elderly being at greatest risk for infection. The success of pneumococcal vaccination programs across Canada can be seen with PCV13 serotypes having declined in all ages, with an overall decline from 45.6% in 2010 to 26.0% in 2014. PCV13 has a significant added benefit over PCV7 in reducing carriage of antibiotic-nonsusceptible Streptococcus pneumonia (ANSP). Because carriage determines transmission, these results suggest that PCV13 will provide protection ANSP disease that exceeds protection provided by PCV7.

Unfortunately, adults are still not effectively protected. The rate of pneumococcal pneumonia in adults 50 to 64 years and ≥65 years is higher among persons with comorbidities vs. healthy counterparts; and a patient’s comorbidities increase their risk of mortality associated with pneumococcal disease. NACI recently published recommendations for pneumococcal vaccinations that will hopefully contribute to the prevention of vaccine-type community-acquired pneumonia and IPD in the adult population.

Learning Objectives:

After attending this symposium, participants will be able to:

  • Review the burden of pneumococcal disease and the introduction and impact of pneumococcal vaccinations in Canada.
  • Describe the importance of reducing nasopharyngeal carriage of S. pneumonaie.
  • Examine the unmet need of pneumococcal disease protection in the adult population.
  • Discuss the importance of adult pneumococcal vaccination and review the implementation of NACI recommendations.


  • James Kellner, MD, Professor and Head, Department of Pediatrics, University of Calgary
  • Ron Grossman, MD, Professor of Medicine, University of Toronto, Chief of Medicine, Credit Valley Hospital

The program was co-developed with CPS and Pfizer Canada Inc and was planned to achieve scientific integrity, objectivity and balance.

Wednesday, December 7 — 07:00-08:45


The symposium will focus on the impact of HPV immunization in Canada and the impact upon the Canadian healthcare system. HPV prevention through immunization will be discussed by reviewing current HPV vaccination programs across Canada, exploring the impact of HPV immunization programs on HPV infection and related diseases, reviewing latest international and Canadian statements around the safety of HPV vaccines” and discussing the latest data of the nonavalent HPV vaccine in terms of 2-dose regimen, immunization of males and cost-effectiveness of vaccination.

Learning Objectives:

  • Summarize the real world effectiveness and safety of HPV immunization in Canada.
  • Describe the status and uptake of current Canadian HPV immunization programs.
  • Discuss the latest clinical data of the nonavalent HPV vaccine.
  • Discuss the challenges facing the program in the next 10 years.


  • Marina Salvadori, MD, Pediatric Infectious Diseases, Schulich School of Medicine, University of Western Ontario
  • Marc Steben, MD, Medical Director, Centre de Santé Sexuelle , Montreal

The program was co-developed with CPS and Merck Canada Inc. and planned to achieve scientific integrity, objectivity and balance.

Wednesday, December 7 — 12:45-14:15


As Canada’s population ages, there will be increasing pressures on an already strained health care system to cope and treat older adults. One particular stress on the health care system is the number of seniors experiencing influenza-related complications or hospitalization.

Learning Objectives:

  • Explain the burden and impact of influenza on older adults and on the healthcare system.
  • Explore the importance of frailty for influenza vaccine effectiveness and outcomes, including the impact that prevention could have on improving health and functional outcomes for older adults.
  • Describe the evidence supporting the use of the high-dose influenza vaccine as a new option for Canadian seniors and understand NACI’s position on the choice of influenza vaccines for adults over 65 years of age.


  • Melissa Andrew, MD, Associate Professor, Medicine (Geriatrics) and Community Health & Epidemiology, Dalhousie University
  • Allison McGeer, MD, Microbiologist & Infectious Disease Consultant, Medical Director, Infection Control, Mount Sinai Hospital; Professor, Laboratory Medicine and Pathobiology and Public Health Science, University of Toronto
  • Janet McElhaney, MD, Senior Scientist, Advanced Medical Research Institute of Canada; Professor, Medical Sciences Division, Northern Ontario School of Medicine
  • Shelly McNeil, MD, Clinician Scientist, Canadian Center for Vaccinology; Professor, Department of Medicine (Infectious Diseases), Dalhousie University

The program was co-developed with AMMI Canada and Sanofi Pasteur and was planned to achieve scientific integrity, objectivity and balance.

Wednesday, December 7 — 12:45-14:15


At present, there are no publicly funded programs in Canada for MenB vaccination. There are only two documented programs where MenB vaccination with the 4CMenB vaccine has been provided publicly. In 2014, MenB vaccination was provided by the Ministry of Health and Social Services of Quebec through a targeted program in the Saguenay-Lac-Saint-Jean region based on the high incidence of IMD caused by serogroup B.

In February of 2015, a vaccination program was publicly funded at Acadia University in Nova Scotia in response to an institutional outbreak. Despite the promise of MenB vaccination, there remain several knowledge gaps, specifically the efficacy and effectiveness of the vaccine. Effective protection from MenB depends upon the match between circulating strains and the strain in the vaccine. Furthermore, there is still debate among researchers on whether the MenB vaccine provides community level protection (herd immunity) and the duration of protection. This symposium will present the most recent research evidence on the immunogenicity and safety of MenB vaccination; discuss the potential impact of vaccination on IMD -associated outcomes, and public acceptance.

Learning Objectives:

After attending this symposium, participants will be able to:

  • Describe the burden of MenB disease in Canada.
  • Identify where knowledge gaps exist with regards to the efficacy and effectiveness of vaccination for MenB.
  • Discuss the potential impact of MenB vaccination on IMD -associated outcomes.
  • Discuss public acceptance of MenB vaccination.


  • Julie Bettinger, MD, Associate Professor, Department of Pediatrics, University of British Columbia
  • Joanne Langley, MD, Professor, Department of Pediatrics, Dalhousie University
  • Eve Dubé, MD, Associate Professor, Social and Preventive Medicine, Université Laval

The program was co-developed with CPS, CPHA and GSK and was planned to achieve scientific integrity, objectivity and balance.